“…Many genes have been studied as biomarkers for various diseases and cancer. NIBAN1 is one of these gene, whose expression is unregulated in many cancer and diseases, such as renal cancer ( Majima et al, 2000 ; Adachi et al, 2004 ; Hino, 2004 ; Sun et al, 2007 ; Feng et al, 2019 ), lung cancer ( Ji et al, 2012 ; Zhang N. et al, 2019 ), head and neck carcinoma ( Ito et al, 2010 ), thyroid cancer ( Cerutti et al, 2004 ; Maciel et al, 2005 ; Cerutti et al, 2006 ; Matsumoto et al, 2006 ; Cerutti, 2011 ; Patel et al, 2011 ; Carvalheira et al, 2013 ; Carvalheira et al, 2015 ; Nozima et al, 2019 ), gynecologic cancers ( Yuki et al, 2015 ; Evstafieva et al, 2018 ; Salgado-Albarrán et al, 2019 ; Wang et al, 2020 ; Chen et al, 2021 ), prostate cancer ( Shaw et al, 2016 ; Thomas et al, 2016 ; Pällmann et al, 2019 ), brain cancer ( Miller et al, 2011 ; Qaisiya et al, 2017 ), bladder cancer ( Zhu et al, 2018 ; Jiang et al, 2020 ) and colorectal cancer ( Tan et al, 2021 ; Wang et al, 2021 ). The NIBAN1 expression has also been observed in some diseases such as, renal interstitial fibrosis ( Liu et al, 2014 ; Tang et al, 2019 ; Tang et al, 2021 ), in asthmatic patients treated with glucocorticoids ( Yick et al, 2013 ; Yick et al, 2014 ), arterial diseases ( Chen et al, 2019 ), vasomotor dysfunction ( Luo et al, 2017 ; Yim et al, 2020 ), liver diseases ( Kannangai et al, 2005 ), and pancreatic diseases ( Zhang K. et al, 2019 ).…”